A multicentre observational study of intraperitoneal immunotherapy with KORJUNY® (catumaxomab) in patients with EpCAM-positive malignant ascites

A multicentre observational study of intraperitoneal immunotherapy with KORJUNY® (catumaxomab) in patients with EpCAM-positive malignant ascites - Catu_AWB

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00040202

Enrollment

Registered

2026-06-23

Start date

2026-08-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

R18

Interventions

Group 1: Patients with EpCAM-positive malignant ascites who are being treated with catumaxomab. This is an observational study designed to assess the administration regimen and premedication under rea

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: • Malignant ascites associated with EpCAM-positive tumours • Treatment with catumaxomab • Age 18 years or older • Legal capacity • A written informed consent form from the patient

Exclusion criteria

Exclusion criteria: • Participation in other interventional trials, • Pregnancy or breastfeeding • Individuals who are employed by or have a contractual relationship with the sponsor or investigator • Committal to an institution by court order or administrative decision.

Design outcomes

Primary

Measure	Time frame
aim of study: description of the correlation between the tolerability of catumaxomab therapy and the administration regimen and premedication under real-world conditions	—

Countries

Germany

Contacts

Public ContactMichael Ströhlein

Kliniken der Stadt Köln gGmbH, Krankenhaus Merheim, Klinik für Viszeral-, Tumor-, Transplantations- und Gefäßchirurgie

StroehleinM@klinikenn-koeln.de0221 8907 3770

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Aug 10, 2026